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Adrenocortical carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. In
this study, we evaluated a potential new treatment target for ACC, focusing on the mitochondrial
reduced form of NAD phosphate (NADPH) generator nicotinamide nucleotide transhydrogenase
(NNT). NNT has a central role within mitochondrial antioxidant pathways, protecting cells from
oxidative stress. Inactivating human NNT mutations result in congenital adrenal insufficiency. We
hypothesized that NNT silencing in ACC cells will induce toxic levels of oxidative stress. To explore this,
we transiently knocked down NNT in NCI-H295R ACC cells. As predicted, this manipulation increased
intracellular levels of oxidative stress; this resulted in a pronounced suppression of cell proliferation
and higher apoptotic rates, as well as sensitization of cells to chemically induced oxidative stress.
Steroidogenesis was paradoxically stimulated by NNT loss, as demonstrated by mass spectrometry–
based steroid profiling. Next, we generated a stable NNT knockdown model in the same cell line to
investigate the longer lasting effects of NNT silencing. After long-term culture, cells adapted met-
abolically to chronic NNT knockdown, restoring their redox balance and resilience to oxidative stress,
although their proliferation remained suppressed. This was associated with higher rates of oxygen
consumption. The molecular pathways underpinning these responses were explored in detail by RNA
sequencing and nontargeted metabolome analysis, revealing major alterations in nucleotide syn-
thesis, protein folding, and polyamine metabolism. This study provides preclinical evidence of the
therapeutic merit of antioxidant targeting in ACC as well as illuminating the long-term adaptive
response of cells to oxidative stress. (Endocrinology 159: 2836–2849, 2018)
Adrenocortical carcinoma (ACC) is a rare but ag-gressive malignancy. Most patients present with, or
eventually develop, metastatic disease, which shows
limited or no responsiveness to cytotoxic chemotherapy
(1, 2). A recent randomized trial revealed a median
survival of ,15 months for patients with disseminated
disease receiving combination chemotherapy (3). Glu-
cocorticoid or androgen excess often constitutes an ad-
ditional clinical burden on ACC patients, undermining
their quality of life (1). Unfortunately, the obvious need
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for more effective medical treatment options in ACC
patients remains unmet, despite the remarkable progress
in our understanding of the molecular biology of ACC in
the last two decades (1).
Recent genetic studies have provided new insights into
adrenal pathophysiology, revealing that inactivating
mutations in the gene encoding the antioxidant en-
zyme nicotinamide nucleotide transhydrogenase (NNT)
underlie a rare, hereditary form of primary adrenal in-
sufficiency (4). Affected patients present in early child-
hood with failure to thrive, hypotension, and hypoglycemia,
due to the inability of adrenal glands to produce suf-
ficient cortisol (4). Intriguingly, despite the key role of
NNT in preserving cellular redox balance and its
ubiquitous expression, the adrenal glands are the only
affected organ in most patients; this observation suggests
a selective sensitivity of the adrenal glands to NNT loss
(4, 5). Supportive of this, NNT-deficient mice harbor
adrenal glands with disorganized cortical architecture
and high apoptotic rates in their adrenal zona fas-
ciculata, the location of glucocorticoid synthesis, but no
other abnormality (4).
NNT is a dimeric proton pump that resides in the inner
mitochondrial membrane of eukaryotic cells and uses the
transmembrane proton gradient to catalyze the transfer
of reducing equivalents from reduced NAD (NADH) to
NAD phosphate (NADP)+, according to the reaction:
NADHþNADPþ þHþIntermembrane↔NADþ þNADPHþ
Hþmatrix (6, 7). The reduced form of NADP (NADPH) is an
essential donor of reducing power to the two main mi-
tochondrial antioxidant pathways, the glutathione and
the thioredoxin pathways, which protect the mito-
chondria from the deleterious effects of oxidative stress
with their capacity to detoxify reactive oxygen species
(ROS; e.g., hydrogen peroxide). ROS, the molecular
mediators of oxidative stress, are continuously produced
within the mitochondria by electron leakage along the
respiratory chain complexes and the tricarboxylic acid
(TCA) cycle; in adrenocortical mitochondria, steroido-
genesis represents an important additional source of ROS
(8–11). Excessive levels of oxidative stress lead to irre-
versible DNA, protein, and lipid damage, which can
culminate in apoptotic cell death (Fig. 1A) (13).
Drawing on these data, which indicate a distinct
metabolic vulnerability of the adrenal cortex to oxidative
stress, we explored the value of antioxidant targeting as a
novel therapeutic approach in ACC, focusing on NNT
as a putative treatment target. Interrogating a publicly
available whole-genome gene expression database (12),
we observed that NNT is upregulated in ACCs in
comparison with benign adrenocortical adenomas and
healthy adrenals (Fig. 1B). Therefore, we hypothesized
that NNT silencing in ACC cells will impair their anti-
oxidant capacity and lead to progressive accumulation of
ROS, inducing unsustainable oxidative toxicity within
the mitochondria and eventually triggering cellular ap-
optosis. We also postulated that steroidogenesis will be
suppressed as a result of NADPH depletion and/or in-
creased oxidative stress.
Materials and Methods
Cell culture protocol and cell line validation
NCI-H295R (RRID: CVCL_0458) ACC cells (passage 10 to
25) were cultured under standard conditions using DMEM/
Ham F-12 medium (Gibco/Thermo Fisher, Waltham, MA)
supplemented with 2.5%Nu serum (Corning, New York, NY),
1% penicillin-streptomycin (Gibco/Thermo Fisher), and 1%
ITS+ universal cell culture premix (Corning). Cell line identity
was confirmed through short tandem repeat genetic analysis
performed by the DNA Diagnostics Company (London, United
Kingdom) followed by comparison with genetic profiles pro-
vided by the American Tissue Culture Collection (http://www.
lgcstandards-atcc.org) (Supplemental Table 1).
Small interfering RNA transfection
Transient NNT gene silencing was achieved through
transfection of NCI-H295R cells with small interfering RNA
(siRNA), using Viromer Blue (Lipocalyx, Halle, Germany)
molecules as transfection vehicles. Three alternative siRNAs
targeting different areas of the NNT gene were tried
(HSS118900, HSS118901, and HSS118902; Life Technologies/
Thermo Fisher, Waltham, MA), and the one exhibiting the most
consistent efficiency in knocking down NNT (HSS118902) was
selected for subsequent experiments. HSS118901 was used to
corroborate results in proliferation and apoptosis assays, whose
results are open to confounding by off-target effects. A scrambled
(SCR), nonsense siRNA (Silencer Select 1 negative control; Life
Technologies) was used as negative control (SCR siRNA).
Viromer-siRNA transfection was performed according to the
manufacturer’s instructions in six-well plates (300,000 cells per
well) and 96-well plates (6000 to 8000 cells per well).
Short hairpin RNA transfection
Lentiviral vectors were obtained fromDharmacon (Lafayette,
CO) in a p.GIPZ backbone and contained five short hairpin
RNAs (shRNAs) specific for human NNT (RHS4430-
98851990, RHS4430-98913600, RHS4430-98524425,
RHS4430-101033169, and RHS4430-101025114) under the
control of the cytomegalovirus promoter, as well as the pu-
romycin resistance and green fluorescence protein genes.
Vectors expressing nonsense, SCR shRNA were used as
negative controls. HEK293T cells (packaging cells; RRID:
CVCL_0063) were transfected with the shRNA particles by
Lipofectamine transfection (Thermo Fisher), according to the
manufacturer’s instructions. Cell media containing the viral
particles were collected 48 to 72 hours posttransfection and
used to transduce NCI-H295R cells. Four days after trans-
fection, green fluorescence protein–positive cells were se-
lected in 4 mg/mL puromycin. Transduction efficiency was
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determined by fluorescence microscopy and Western blotting
for NNT expression.
Gene expression
Gene expression for NNT and steroidogenic enzymes was
evaluated at a transcriptional level by quantitative real-time PCR
(qRT-PCR). RNA extraction was performed using the RNeasy
Mini kit (Qiagen, Hilden, Germany) following the manufacturer’s
instructions. Reverse transcription to generate cDNA was carried
out using the Tetro cDNA synthesis kit (Bioline, London, United
Kingdom), following the manufacturer’s instructions (500 to
2000 ng of RNA per reaction was used). cDNA concentration was
determined by use of a fluorescent DNA dye (Quant-iT PicoGreen
double-stranded DNA reagent, Thermo Fisher), comparing sample
fluorescence to the fluorescence exhibited by a dilution series of
samples of known concentrations (Wallac Victor 1420 multilabel
counter). Gene expression was then quantified by qRT-PCR using
the the TaqMan gene expression system (Thermo Fisher). Reactions
Figure 1. (A) Interaction between NNT and the mitochondrial antioxidant pathways. (B) NNT expression in patients with ACC (n = 33),
compared with patients with adrenocortical adenomas (n = 22) and healthy adrenals (n = 10). Gene expression was quantile normalized and log
transformed as described (12); bars represent median and interquartile range. Gene expression across groups was compared by applying the
Kruskal–Wallis test, followed by a post hoc Bonferroni test. **P , 0.01. ATP, adenosine triphosphate; ETC, electron transfer chain; GPX1,
glutathione peroxidase 1; GSR, glutathione reductase; H2O2, hydrogen peroxide; O2
$2, superoxide; SOD2, superoxide dismutase 2; PRDX3,
peroxiredoxin 3; TXN, oxidized thioredoxin; TXNRD2, thioredoxin reductase 2; TXN-SH, reduced thioredoxin.
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were run in a ABI 7500 qRT-PCR analyzer [50°C incubation for
2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for
15 seconds (denaturation) and then 60°C for 1 minute (annealing–
extension); Applied Biosystems/Thermo Fisher, Foster City, CA]. All
reactions were normalized against the housekeeping gene RPLPO
(large ribosomalprotein).Dataare expressedasDCtvalues [DCt= (Ct
of the target gene) – (Ct of the housekeeping gene)] or fold change to
control cells (22DDCt), where DDCt = DCt [NNT knockdown (KD)
cells] – DCt (control cells).
Protein expression
Protein lysate generation was performed by applying radio-
immunoprecipitation assay buffer (Sigma-Aldrich, St. Louis,MO)
with protease inhibitor cocktail (Sigma-Aldrich) to adherent cells
grown in six-well plates and subsequent collection by scraping.
Total protein concentration was estimated colorimetrically using
the BCA protein assay kit (Thermo Fisher) as per the manufac-
turer’s instructions, measuring absorbance at 560 nm (1420
multilabel counter; Wallac Victor). NNT protein expression level
was assessed byWestern blotting. Samples were run in 10% SDS-
PAGE gels (Thermo Fisher) and transferred to a nitrocellulose
membrane using the iBlot dry transfer system (Thermo Fisher).
Membranes were subsequently probed with anti-NNT anti-
body produced in rabbit (HPA004829; Sigma-Aldrich; RRID:
AB_1079495) at a 1:500 dilution and secondary anti-rabbit
antibody (sc-2030; Santa Cruz Biotechnology, Dallas, TX;
RRID: AB_631747) at a 1:2000 dilution. b-Actin was used as
control protein (primary antibody A5441; RRID: AB_476744)
from Sigma-Aldrich and secondary anti-mouse antibody from
Santa Cruz Biotechnology (sc-2005; RRID: AB_631736) at di-
lutions of 1:10,000 and 1:20,000, respectively.
Reduced to oxidized glutathione ratio
Total cell glutathione [reduced glutathione (GSH) plus
oxidized glutathione (GSSG)] and GSSG were measured by
luminescence in cells growing in opaque-walled 96-well plates,
using the GSH/GSSG-Glo assay (Promega, Madison, WI)
according to the manufacturer’s instructions. The resulting
luminescent signal was measured in a Wallac Victor 1420
multilabel counter, using triplicate samples per treatment group
and subtracting blank measurements to produce net results.
GSH/GSSG ratios were calculated directly from net relative
luminescence unit (RLU) measurements using the equation:
GSH/GSSG ratio = (Net total glutathione RLUs 2 Net GSSG
RLUs)/(Net GSSG RLUs/2).
Metabolic flux analysis (Seahorse XF)
Metabolic flux analysis in a Seahorse XF 24 analyzer was used
to assess the effect of NNT KD on mitochondrial bioenergetics,
applying the Seahorse XFCellMito Stress kit (Agilent, Santa Clara,
CA). Cells were plated in Seahorse XF microplates the day before
the experiment at a density of 100,000 cells per well. Changes in
oxygen concentration provide the oxygen consumption rate
(OCR), which is a measure of mitochondrial respiration. Changes
in proton concentration (or pH) provide the extracellular acidifi-
cation rate (ECAR), reflective of the rate of glycolysis. Measure-
ments were taken at baseline and after successive application
of compounds interfering with oxidative phosphorylation:
oligomycin (complex V inhibitor, 2 mM), carbonyl cyanide-
p-trifluoromethoxyphenylhydrazone (mitochondrial uncoupler,
1mM), and antimycin A plus rotenone (complex I and III inhibition,
1 mM). Results were normalized to protein concentration, measured
by the BCA protein assay kit (Thermo Fisher).
Cell proliferation and apoptosis
Cell proliferation was assessed in 96-well plates (loading
concentration of 6000 to 8000 cells per well) using the CyQuant
proliferation assay kit (Thermo Fisher) and following the
manufacturer’s instructions. Cell DNA fluorescence was mea-
sured at the end of the time course, that is, 166 hours after
siRNA transfection and/or 96 hours after treatment. The be-
ginning of treatment was used as the baseline time point (t = 0)
for each proliferation series; for siRNA KD experiments,
72 hours posttransfection was taken as the baseline time point.
Proliferation rates were provided by the following ratio: (end
cell number 2 baseline cell number)/baseline cell number.
Cellular apoptosis was assessed using the Caspase-Glo 3/7
assay kit (Promega), a luminescence-based assay measuring
caspase-3 and caspase-7 activity in cell lysates, and following
the manufacturer’s instructions. Luminescent signals were
quantified using the Wallac Victor 1420 multilabel counter. At
the end of the assay, media and reagents were removed from all
wells and stored at280°C. The next day, relative quantification
of cell number was performed by use of the CyQuant pro-
liferation assay kit, as described above. Luminescence values
obtained in the caspase assay were normalized to the fluores-
cence results of the proliferation assay.
Paraquat and auranofin were purchased from Sigma-
Aldrich. Buthionine sulfoximine (BSO) was purchased from
Cayman Chemical (Ann Arbor, MI).
In vitro steroid profiling by liquid
chromatography–tandem mass spectrometry
Steroid synthesis by NCI-H295R cells was assessed by
comprehensive multisteroid profiling employing liquid
chromatography–tandem mass spectrometry (LC-MS/MS), as
described previously (14, 15). Steroid extraction and analysis by
LC-MS/MS are discussed in Supplemental Methods.
RNA sequencing
RNA was prepared in triplicate from NCI-H295R KD
siRNA, SCR siRNA (72 hours posttransfection), KD shRNA,
and SCR shRNA cells using the RNeasy Mini kit (Qiagen). Li-
braries were generated using the TruSeq stranded mRNA library
prep kit (Illumina, San Diego, CA). A 4 nM library (containing
the 16 pooled libraries) was sequenced on a NextSeq 500 system
(Illumina). Pathway analyses on sequencing data were completed
using the GAGE v2.22 package from Bioconductor release
3.2 and referencing the KEGGpathways. Differentially expressed
genes were considered significant applying a false discovery rate
of,5% (q, 0.05). Differentially regulated pathwayswere called
at a P value of,0.01. A detailed description of the methodology
for RNA sequencing and pathway analysis can be found in
Supplemental Methods.
Additionally, RNA sequencing data from recently published
work on three different mouse strains [Nnt inactivating mu-
tation, C57BL/6J (RRID: MGI:3702942); wild-type, C57BL/
6NHsd (RRID: MGI:2161078); and transgenic Nnt over-
expressor, C57BL/6JBAC] (16) were reanalyzed employing
the same pathway analysis as for the human cell–based
model; detailed information on this dataset can be found in
Supplemental Methods.
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Metabolome analysis
Cell and media samples were prepared for nontargeted
metabolome analysis through quenching cell metabolism with a
mix of acetonitrile, methanol, and water (Sigma-Aldrich). The
process of sample generation and analysis is described in more
detail in Supplemental Methods.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
7 software (RRID: SCR_002798). Data are represented as
means 6 SEM values, unless otherwise stated. Comparisons
were made using a Student paired t test for normally dis-
tributed data or Wilcoxon signed-rank test for data not
following a Gaussian distribution. Multiple comparisons
(BSO and auranofin treatments) were performed by one-
way ANOVA followed by post hoc multiple compari-
son testing. Statistical methods for the RNA sequencing
and untargeted metabolome analysis are detailed in
Supplemental Methods.
Results
Transient and stable NNT KD
Transient NNT silencing by siRNA KDwas employed
to explore the acute effects of NNT loss on ACC cells.
NNT siRNA transfection in NCI-H295R cells yielded
efficient gene silencing for at least 166 hours post-
transfection with two different siRNAs (Supplemental
Fig. 1A and 1B). All subsequent experiments were per-
formed with the siRNA that gave the best KD results on
real-time PCR and Western blotting (referred to here as
KD siRNA). The second siRNA (KD siRNA2) was used
to corroborate the results of proliferation and apoptosis
assays, whose results are most likely to be distorted by
off-target effects.
Stable NNT silencing by shRNA KD was used to
delineate the long-term effects of NNT loss on ACC cells.
Stable NNT KD in NCI-H295R cells was achieved by
lentiviral transfection with shRNA-expressing plasmids
and selection with puromycin, and resulted in permanent
NNT silencing (Supplemental Fig. 1C and 1D).
NNT siRNA KD increases cellular oxidative stress
Given the central role of NNT within the mitochon-
drial ROS scavenging network, we hypothesized that
NNT KD will increase oxidative stress in NCI-H295R
cells. To test this, we measured the intracellular GSH/
GSSG ratio, an established marker of oxidative stress;
a decrease in the GSH/GSSG ratio indicates that the
proportion of oxidized intracellular glutathione is in-
creased as a result of higher intracellular ROS levels.
Indeed, we observed a statistically significant (P , 0.05)
decrease in the GSH/GSSG ratio in NNT KD siRNA-
transfected cells 96 hours posttransfection (Fig. 2A).
Figure 2. Effects of transient (siRNA-mediated) NNT silencing on NCI-H295R cell redox balance, respiration, proliferation, and viability. Bars
represent means 6 SEM values, unless stated otherwise. (A) GSH/GSSG ratio in NCI-H295R cells transfected with KD siRNA (96 hours
posttransfection), normalized to the corresponding ratio of SCR siRNA-transfected cells. Significant suppression of the GSH/GSSG ratio in KD
siRNA cells suggests higher intracellular oxidative stress. Bars represent medians 6 interquartile range values. *P , 0.05 (n = 8 independent
experiments). (B) Proliferation rates observed in siRNA-transfected NCI-H295R cells, 72 to 166 hours posttransfection. ***P , 0.001 (n = 14). (C)
Caspase-3/caspase-7 activity ratio in KD siRNA cells to SCR siRNA-transfected cells, after standardization to cell numbers (120 hours posttransfection).
*P , 0.05 (n = 8). (D) Seahorse XF24 analysis of cellular OCR at baseline and after successive application of three mitochondrial respiration inhibitors
(166 hours posttransfection). Results were standardized to protein concentration. Bars represent medians 6 interquartile range values. P . 0.05 (n =
4). (E) ECAR, surrogate marker of anaerobic glycolysis, standardized for protein concentration. P . 0.05 (n = 4). (F) Proliferation under low-dose
chemically induced oxidative stress (paraquat 10 mM) in KD siRNA and SCR siRNA-transfected cells, normalized to corresponding cell proliferation
without paraquat treatment. *P , 0.05 (n = 6). A&R, antimycin A plus rotenone; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone;
O/mycin, oligomycin.
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NNT siRNA KD suppresses cell proliferation and
induces apoptotic cell death
Cell proliferation rates were assessed during the time
window from 72 to 166 hours posttransfection, a period
with consistent NNT KD confirmed at the protein level
(Supplemental Fig. 1). NNT KD by KD siRNA trans-
fection led to a marked decrease in cellular proliferation
rates (Fig. 2B). These results were corroborated by use
of a second siRNA against NNT, which completely
obliterated cell proliferation (Supplemental Fig. 2).
To establish whether the increased oxidative stress
observed with NNT KD leads to higher rates of apo-
ptosis, as predicted by ROS physiology, we measured
intracellular caspase-3 and caspase-7 activity 120 hours
posttransfection.We also quantified relative cell numbers
by DNA fluorescence at the same time point to stan-
dardize results to cell number. NNT KD siRNA cells
exhibited significantly higher caspase-3/caspase-7 activ-
ity than did SCR siRNA cells (P, 0.05), confirming our
hypothesis that NNT KD triggers cell death by apoptosis
(Fig. 2C). The effect was even more marked with the
alternative siRNA against NNT (Supplemental Fig. 2).
NNT siRNA KD sensitizes cells to oxidative stress
Next, we evaluated changes in mitochondrial respi-
ration by direct measurement of the cellular OCR using
extracellular flux analysis. Despite the location of NNT
in the inner mitochondrial membrane, we observed no
statistically significant difference between NNT KD
siRNA- and SCR siRNA-transfected cells, either at
baseline or in response to mitochondrial respiration
disruptors (Fig. 2D). Baseline ECAR, representative of
the glycolytic rate, was also similar between the two
groups (Fig. 2E).
Considering the integral role of NNT in mitochon-
drial antioxidant defense and the detrimental impact of
NNT inhibition on redox balance, we further hypoth-
esized that NNT loss will render NCI-H295R cells more
sensitive to chemically induced oxidative stress. To
assess this assumption, we treated NCI-H295R cells
with a subtoxic dose of paraquat, a pesticide that in-
duces oxidative stress in vitro, generating superoxide.
Treatment with 10 mM paraquat for 96 hours led to a
statistically significant decrease in cell proliferation in
cells transfected with KD siRNA, but not in their
counterparts that had been transfected with SCR siRNA
(Fig. 2F).
Redox adaptation develops with stable NNT KD
To explore the long-term metabolic consequences
of NNT silencing in NCI-H295R cells, we employed a
different model involving stable transfection with shRNA
against NNT. With long-term culture under persistent
NNT silencing (4 to 12 weeks posttransfection), cells
managed to restore their redox balance to the levels of
their SCR shRNA-transfected counterparts (Fig. 3A).
Figure 3. Effects of stable (shRNA-mediated) NNT silencing on NCI-H295R cell redox balance, respiration, proliferation, and viability. Bars
represent means 6 SEM values, unless stated otherwise. (A) GSH/GSSG ratio in NCI-H295R cells transfected with KD shRNA, normalized to the
corresponding ratio cells transfected with SCR shRNA. Bars represent medians 6 interquartile range values. P . 0.05 (n = 10). (B) Proliferation
rates during a 96-hour period. *P , 0.05 (n 5 13). (C) Caspase-3/caspase-7 activity ratio in KD shRNA cells to SCR shRNA-transfected cells, after
standardization to cell numbers. P . 0.05 (n = 4). (D) Seahorse XF24 analysis of cellular OCR at baseline and after successive application of
three mitochondrial respiration inhibitors. Results were standardized to protein concentration. Bars represent medians 6 interquartile range values.
*P , 0.05 (n = 7). (E) ECAR standardized for protein concentration. P . 0.05 (n = 7). (F) Proliferation under chemically induced oxidative stress
(paraquat) in KD shRNA and SCR shRNA cells, normalized to corresponding cell proliferation without paraquat treatment. P . 0.05 (n = 13). A&R,
antimycin A plus rotenone; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; O/mycin, oligomycin.
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ACC proliferation remains suppressed with stable
NNT KD
The distinctmetabolic consequences ofNNT silencing in
the stable KD setting, in comparison with acute KD by
NNT siRNA, translated into an attenuated response with
respect to cellular proliferation and viability. Proliferation
rates remained significantly lower inKD shRNA-transfected
cells compared with the SCR shRNA-transfected controls;
however, this effect was less pronounced than the decrease
in proliferation we observed with siRNA-mediated KD
(Fig. 3B). Apoptotic rates did not differ between SCR
shRNA and KD shRNA cells (Fig. 3C), in keeping with the
restoration of redox homeostasis we had ascertained based
on the GSH/GSSG ratio.
Interestingly, NNT KD shRNA cells consumed more
oxygen than did SCR shRNA cells at baseline (Fig. 3D).
This finding potentially reflects higher energy needs in
NNT-deficient cells. The same trend was observed in
ECAR, a surrogate marker of glycolysis, but without
reaching statistical significance (Fig. 3E). Finally, stable
NNT KD did not enhance cell sensitivity to oxidative
stress induced by paraquat (Fig. 3F).
Transient, but not stable, NNT KD paradoxically
stimulates steroidogenesis
The effects of NNT silencing on steroidogenesis were
evaluated by comprehensive multisteroid profiling in
cell media by LC-MS/MS, as well as gene expression
analysis by qRT-PCR.We postulated that NNT silencing
will disrupt steroidogenesis, either depriving mitochon-
drial steroidogenic monooxygenases [cholesterol side-
chain cleaving enzyme (CYP11A1), 11b-hydroxylase
(CYP11B1), aldosterone synthase (CYP11B2)] of their
essential electron donor NADPH, or due to oxidative
stress–induced downregulation of key steroidogenic en-
zymes. Surprisingly, NNT KD siRNA-transfected cells
actually produced significantly more glucocorticoids
(cortisol) and androgens (androstenedione) than did
controls (Fig. 4A and 4B). Individual enzyme activities
were determined as product-to-substrate ratios for three key
steroidogenic enzymes, 11b-hydroxylase (CYP11B1), 21-
hydroxylase (CY21A2), and CYP17A1 17/20-lyase
activity; all three displayed higher activity in NNT
KD siRNA-transfected cells, in keeping with a para-
doxical generalized stimulation of steroidogenesis by
acute NNT loss (Fig. 4C–4E).
In contrast, in the shRNA-transfected cells with chronic
NNT silencing we observed no significant impact on
steroidogenesis, with similar rates of cortisol or andros-
tenedione synthesis between KD shRNA and SCR shRNA
cells (Fig. 4A–4E).
We also explored the gene expression alterations
underpinning the enhanced steroid production of cells
transfected with KD siRNA, comparing the expression of
core steroidogenic genes (StAR, CYP11A1, CYP21A2,
CYP17A1, 3bHSD2) between KD siRNA and SCR siRNA
cells by qRT-PCR. There was a statistically significant in-
crease in the expression of cytochrome P450 (CYP) type
2 steroidogenic enzymes located in the endoplasmic retic-
ulum (ER) CYP21A2 (P, 0.05), CYP17A1 (P, 0.05), as
well as the ER dehydrogenase HSD3B2 (P, 0.01) in NNT
KD siRNA cells (Supplemental Table 2). CYP11B1 and
CYP11B2 expression levels were too low to be quantified
by qRT-PCR in our cells.
Analysis of gene expression by RNA sequencing in
an extended panel of 14 steroidogenic genes indicated a
significant upregulation of CYP21A2 (q , 0.05) and
CYP17A1 (q, 0.01), aswell as theACTH receptorMC2R
(q, 0.01), in the transient NNT KD model; no significant
changes were observed in the stable KD model (Fig. 4F).
NCI-H295R cells are sensitive to glutathione
depletion and thioredoxin reductase inhibition
Given the effects of NNT inhibition on NCI-H295R
cell proliferation, we went on to evaluate the sensitivity of
ACC cells to isolated inhibition of each of the two pillars
of mitochondrial antioxidant defense: the glutathione
pathway and the thioredoxin pathway.
We used BSO, a potent inhibitor of the glutathione-
producing enzyme c-glutamylcysteine ligase, to deplete
intracellular glutathione. We observed a decline in cell
proliferation with a BSO dose of$100 mMafter 96 hours
of treatment (Fig. 5A).
Pharmacological manipulation of the alternative mi-
tochondrial antioxidant pathway, the thioredoxin path-
way, was achieved by auranofin, a gold complex agent
with a well-established capacity to inhibit thioredoxin
reductase. NCI-H295R treatment with doses of $1 mM
was associated with major cytotoxicity (Fig. 5B).
Finally, dual inhibition of the glutathione and thio-
redoxin pathways by coadministration of low-dose BSO
(50 mM) and auranofin (0.2 mM) resulted in marked
cytotoxicity, suggesting that a potent synergistic effect
can be achieved by dual pathway targeting (Fig. 5C).
Whole-transcriptome and metabolome analyses
reveal extensive metabolic perturbations with
transient NNT KD, as well as changes in protein
processing and polyamine metabolism with stable
NNT KD
To uncover the molecular mechanisms that underpin
the effects we observed in the two models and the
discrepancies between them,we appliedwhole-transcriptome
analysis inRNAextracted from four groups of NCI-H295R
cells (NNT KD siRNA vs SCR siRNA, NNT KD
shRNA vs SCR shRNA). Eight hundred forty-two
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genes were differentially regulated between NNT KD
siRNA and SCR siRNA cells; 247 genes were differ-
entially regulated between NNT KD shRNA and SCR
shRNA cells (q , 0.05). Of note, only 17 of the genes
regulated differentially between KD and SCR cells were
identical in the two models, NNT KD siRNA and
shRNA (Supplemental Table 3).
Differentially regulated pathways are shown in Fig. 6A
and 6B (P, 0.01) and tabulated in Supplemental Table 4.
In NNT KD siRNA cells, significant changes were ob-
served in crucial pathways affecting cellular proliferation
and viability (p53 pathway, mitogen-activated signaling
kinase pathway, checkpoint kinases). Interestingly, in KD
shRNA cells one of the borderline significantly altered
pathways (P , 0.01, q = 0.11) controlled protein pro-
cessing in the ER, with upregulation of genes encoding
heat shock proteins (predominantly in the HSP40 family),
chaperone proteins that facilitate correct protein folding,
and transfer of misfolded proteins to proteasomes for
degradation (Supplemental Table 4) (17, 18). Other sig-
nificantly upregulated pathways with stable NNT KD
included ribosomal genes (P , 0.01, q , 0.05) and py-
rimidine metabolism (P , 0.01, q = 0.11), including an
upregulation of RNA II polymerases. Taken together,
Figure 4. Effects of NNT silencing on NCI-H295R steroidogenesis, delineated by LC-MS/MS steroid profiling in serum-free cell media and RNA
sequencing. (A) Cortisol production and (B) androstenedione production during a 48-hour period in NCI-H295R cells transfected with siRNA or
shRNA are shown. A significant stimulation of cortisol and androstenedione synthesis was observed 72 to 120 hours posttransfection with KD
siRNA. *P , 0.05; **P , 0.01 (n $ 5). (C–E) Specific enzyme activity derived from product-to-substrate ratios for (C) 11b-hydoxylase (CYP11B1),
(D) 21-hydroxylase (CYP21A2), and (E) 17,20-lyase (CYP17A1) in siRNA and shRNA-transfected cells. **P , 0.01; ***P , 0.001 (n $ 5). (F)
Heat map representation of steroidogenic gene expression changes induced by transient and stable NNT KD, as revealed by RNA sequencing.
Scale represents log2 fold changes in NNT KD cells compared with their respective (siRNA or shRNA) SCR controls. *q , 0.05; **q , 0.01 (n = 3).
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these findings hint at a higher protein turnover that may
allow cells to swiftly replace proteins that have sustained
irreversible oxidative damage.
Of note, recent rodent-based work by Meimaridou et al.
(16) performed RNA sequencing on mouse adrenal glands
derived from three different mouse strains: a strain that
carries an inactivating mutation ofNnt (C57BL/6J), a strain
with wild-type Nnt expression (C57BL/6N), and transgenic
mice overexpressing Nnt on the background of the NNT-
deficient mouse strain (rescue model; C57BL/6JBAC). We
have extended this work in the present study, carrying out
additional pathway analyses on these data. Detailed in-
formation on significantly dysregulated pathways in C57BL/
6J vs C57BL/6N mice and C57BL/6J vs C57BL/6JBAC mice
are presented in Supplemental Table 5. Significant dysre-
gulation of the major cell signaling pathway of mitogen-
activated signaling kinases was one of the salient molecular
changes in both comparisons; the same pathway was also
dysregulated with transient NNT KD in NCI-H295R cells.
Oxidative phosphorylation was upregulated in both com-
parisons, but changes were much more pronounced in the
C57BL/6J vs C57BL/6N comparison and likely to reflect a
strain, rather than gene, effect.
RNA sequencing in NCI-H295R cells was complemented
by whole-metabolome analysis performed separately in cells
and corresponding cell culture supernatant. In the siRNAKD
model, NNT silencing was associated with a significant
metabolic perturbationwhen comparedwith the SCR siRNA
cells. An increase in the presence of 44 oxidized fatty acids
supports a shift to a more oxidized intracellular microenvi-
ronment (Fig. 6C; Supplemental Tables 6 and 7). This was
not observed in the stable NNT KD model. Pathway en-
richment analysis demonstrated that six important metabolic
pathways were enriched (q, 0.05): TCA cycle, arginine and
proline metabolism, pyrimidine metabolism, nicotinate and
nicotinamide metabolism, and glutathione metabolism. Be-
yond this, we observed statistically significant changes (q ,
0.01) for 16 acyl carnitines, 25 fatty acids, 15 acyl amino
acids, 20 purine and pyrimidine metabolites, and 5 metab-
olites present in the nicotinate and nicotinamide metabolic
pathways. Taken together, these findings indicate a pertur-
bation in mitochondrial fatty acid b-oxidation (as shown by
Figure 5. Effect of glutathione and thioredoxin pathway inhibition on NCI-H295R cell proliferation. (A) Ninety-six–hour treatment with
incremental doses of BSO (0 to 200 mM), an inhibitor of glutathione synthesis. Control cells were treated with vehicle only. *P , 0.05 (n = 9).
(B) Ninety-six–hour treatment with incremental doses of auranofin (0 to 5 mM), a thioredoxin reductase inhibitor. Control cells were treated with
vehicle only. Negative proliferation rates indicate net decrease in cell number after 96 hours of treatment. **P , 0.01; ****P , 0.0001 (n = 9).
(C) Combined glutathione and thioredoxin inhibition by use of low-dose BSO (50 mM) and auranofin (0.2 mM). *P , 0.05 (n = 3).
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changes in fatty acids, acyl carnitines, and TCAmetabolites),
changes in nucleotide synthesis, and a potential overload of
acetyl units.
In the stable NNT shRNA KD model, pathway en-
richment analysis highlighted changes in purine metabolism
(q , 0.05), and NNT KD cells exhibited a significant (P ,
0.05) rise in several purine and pyrimidine metabolites
(Fig. 6D; Supplemental Tables 6 and 7),mirroring the results
of the transcriptomeanalysis. Polyamine (spermine, spermidine)
metabolism was also significantly modified in both
models: KD siRNA cells displayed a dramatic increase in
polyamine catabolism (accumulation of diacetyl-spermine,
diacetyl-spermidine, spermine dialdehyde), leading to de-
pletion of spermine and spermidine, a response that has been
associated with arrest of cell growth (Supplemental Tables 6
and 7) (19). Conversely, KD shRNA cells exhibited a sig-
nificant rise in spermine, a polyamine that can act as an ROS
scavenger (20, 21).
Discussion
In this study, we have explored the immediate and longer
term impact of NNT silencing onACC cells with respect to
redox balance, mitochondrial bioenergetics, cell pro-
liferation and viability, and steroidogenesis, using two
distinct in vitro KD models in the human ACC cell line
NCI-H295R. Our aim was to establish whether NNT
inhibition can have therapeutically beneficial effects with
respect to control of tumor growth and steroid excess. We
hypothesized that NNT inhibition would compromise the
ability of adrenocortical mitochondria to deal with oxi-
dative stress, leading to progressive accumulation of ROS.
ROS excess has multiple toxic sequelae and can directly
impair cell viability, triggering apoptosis (8, 13). Impor-
tantly, the adrenal-specific clinical phenotype in humans
and the reported increased rate of adrenocortical cell
apoptosis in otherwise healthy NNT mutant mice suggest
that this manipulation may selectively target ACC cells,
sparing other organs. This susceptibility of adrenocortical
cells to mitochondrial antioxidant pathway disruption
can be explained by the fact that enzymes involved in the
rapid adrenal steroid response to stress represent a major
additional source of ROS in the adrenals, increasing their
dependence on efficient ROS scavenging (10, 11).
In keeping with our hypothesis, we found that in the
acute setting (siRNA-mediated transient KD), NNT loss
Figure 6. Whole-transcriptome sequencing and nontargeted metabolome analysis of KD siRNA, SCR siRNA, KD shRNA, and SCR shRNA-transfected
NCI-H295R cells. (A and B) Whole-transcriptome sequencing in siRNA and shRNA-transfected NCI-H295R cells. (A) Significantly altered molecular
pathways (P , 0.01, q , 0.05) between KD siRNA and SCR siRNA cells and number of associated genes that are upregulated/downregulated in KD
siRNA cells. (B) Significantly altered molecular pathways (P , 0.01) between KD shRNA and SCR shRNA cells and number of associated genes that
are upregulated/downregulated in KD shRNA cells. (C and D) Nontargeted metabolome analysis in siRNA and shRNA-transfected NCI-H295R cells. (C)
Significantly upregulated and downregulated intracellular metabolites (q , 0.01) in KD siRNA-transfected cells, as compared with SCR
siRNA-transfected cells. (D) Significantly upregulated and downregulated intracellular metabolites (P , 0.05) in KD shRNA-transfected cells,
as compared with SCR shRNA-transfected cells (no metabolites with q , 0.05 in this comparison).
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increased intracellular oxidative stress. Redox balance
perturbations in response to NNT loss have been pre-
viously demonstrated in a limited number of cell lines in
vitro, as well as in lymphocytes derived fromNNTmutant
patients ex vivo (4, 22–25). These findings are in line with
the biological role of NNT as a major mitochondrial
generator of NADPH, the essential provider of reducing
equivalents to the two main antioxidant pathways (26).
Importantly, in our study we observed that NNT si-
lencing led to an immediate and marked inhibition of cell
proliferation accompanied by increased apoptotic rates.
This antitumor effect was even more pronounced when
using a second anti-NNT siRNA (KD siRNA2). This
apparent difference in degree (but not in direction) of cell
response raised the possibility of additional, off-target
effects triggered by KD siRNA2; on interrogation of the
National Center for Biotechnology Information Basic
Local Assignment Search Tool, however, neither of the
two siRNAs shares substantial homology with any genes
that would be expected to impact cell proliferation and
viability. The association between excessive oxidative
stress and mitochondrial apoptosis has been well estab-
lished in the literature (8, 13), but data on the effects of
NNT loss on cellular proliferation and viability are lim-
ited. Transient NNT silencing was previously shown to
increase rates of apoptosis in PC12 (rat pheochromocy-
toma) cells (22); stableNNTKD in humanmelanoma cells
was associated with reduced viability and high apoptotic
rates in vitro, as well as slower growth of melanoma
xenografts in mice (27). Meimaridou et al. (4) reported
high levels of apoptosis in the zona fasciculata of the
adrenal cortex from NNT mutant mice, as well as NCI-
H295R cells stably transfected with shRNA against NNT
in vitro. Although ROS have typically been associated
with a stimulation of cellular proliferation, a number of
in vitro models have demonstrated the opposite effect
(suppression of cell division), in a complex relationship
that may depend on the magnitude of ROS excess and/or
tissue type (28, 29). NNT inhibition may also interfere
with cellular proliferation in a ROS-independent way,
curtailing the amount of NADPH available to fuel the
pressing anabolic needs of malignant cells. In keeping with
themajor impact on cellular viability and proliferation, we
observed far-reaching metabolic effects of NNT KD im-
plicating several areas of cell metabolism, including mi-
tochondrial fatty acid oxidation, polyamine metabolism,
and nucleotide synthesis. The enhanced cellular sensitivity
to oxidative stress in the aftermath of NNT silencing
(paraquat treatment) is translationally important, as ox-
idative stress is induced by a number of classic chemo-
therapy agents, contributing to their cytotoxic effect (8,
30). NNT inhibition could represent a feasible strategy to
sensitize ACC to such drugs.
The longer term effects of NNT loss on ACC cells, as
delineated in the stable KD model, were disparate from the
ones encountered in the acute setting. Importantly, with
long-term culture under constant NNT silencing, NCI-
H295R ACC cells managed to restore their redox bal-
ance. This compensation abrogated the proapoptotic early
impact of NNT loss. Interestingly, a persistent proliferative
handicap was demonstrated, although this was less marked
than the one observed in the acute setting. This may be
attributable to the limited supply of NADPH in the absence
of NNT. Extracellular flux analysis revealed higher rates of
oxygen consumption in KD shRNA cells, a response that
may reflect higher energy needs or be driven by the spare
NADH that fails to be converted to NADPH in NNT-
deficient cells. Previous studies on the effect of NNT si-
lencing on oxygen consumption have shown mixed results,
which may be cell type–dependent (22, 25, 31).
Redox adaptation to oxidative stress has been pre-
viously described in tumor models in vitro; this process is
driven by the strong selective pressure applied by oxi-
dative toxicity and promoted by the genomic instability
that characterizes the oxidized intracellular microenvi-
ronment (32). We obtained insights into how this ad-
aptation was facilitated in our model by comprehensive
transcriptome and metabolome analysis. In NNT KD
shRNA cells, we observed an upregulation of genes that
are involved in protein folding in the ER, as well as in the
identification and degradation of damaged proteins.
Purine and pyrimidine metabolism was activated in these
cells, and ribosomal genes were upregulated. Taken to-
gether, these findings hint at increased protein turnover,
involving degradation of damaged protein and acceler-
ation of new protein synthesis. This may represent a key
compensatorymechanism against oxidative stress, achieving
the timely removal and replacement of irrevocably damaged
(oxidized) proteins. The observed increase in oxygen con-
sumption could provide additional energy to fuel this pro-
cess. Of note, we recently described upregulation of
chaperone proteins in the adrenals of NNT-deficient mice
(16). The additional pathway analysis we performed on the
same RNA sequencing data from that rodent work dis-
played otherwise limited overlap with our in vitro model,
likely reflecting the expected biological differences between a
healthy mouse adrenal and a malignant human adrenal
cell line.
Interestingly, polyamine metabolism exhibited dra-
matic shifts in opposite directions in the two models.
Polyamines (spermine, spermidine) are versatile cationic
molecules involved in a number of cell processes, including
ROS scavenging and cell proliferation (19, 33). High
endogenous polyamine levels have been found in a number
of cancer types (34). Acute NNT loss was accompanied
by a rapid accumulation of acetylated catabolic products
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of polyamines, leading to depletion of spermine and
spermidine. Polyamine catabolism can both be triggered
by oxidative stress and generate hydrogen peroxide,
creating a vicious cycle that propagates ROS accumulation
(33, 35). Indeed, stimulated polyamine catabolism has
been associated with growth arrest and cell death in
various in vitromodels (19, 36). Conversely, in the chronic
setting, stable NNT KD cells demonstrated increased
spermine concentrations and no evidence of accelerated
polyamine catabolism. This response is likely to represent
a major facilitator of the successful redox adaptation in
this model. Our findings underscore the importance of
polyamine homeostasis in ACC cells.
Within the same framework, we also explored alter-
native antioxidant targets focusing on the glutathione and
thioredoxin pathways. Pertinently, human mutations in
thioredoxin reductase 2 have also been shown to result
in isolated glucocorticoid deficiency (37). We used BSO
to inhibit glutathione synthesis. BSO has shown anti-
proliferative effects against a number of cell lines in vitro
(38–43). We observed a significant suppression of cell
growth with doses of $100 mM, that is, at doses that are
clinically attainable in plasma with no serious toxicity (38).
Auranofin, a gold complex–based agent able to inhibit
thioredoxin reductase, also suppressed cell proliferation at
doses$1mMandwas associated withmarked cytotoxicity
at doses of $2 mM. Auranofin has also displayed antitu-
mor activity against a number of cell lines in vitro and is
currently being investigated in clinical
trials against leukemia (44–47). Apply-
ing combined treatment with low doses
of both agents, we observed a dramatic
cytotoxic impact, suggesting that dual
antioxidant targeting can achieve potent
synergistic results.
The observed effects of NNT si-
lencing on NCI-H295R steroidogenesis
were surprising. In the acute setting,
that is, NNT siRNA KD, we observed
a generalized stimulation of steroido-
genesis, leading to increased glucocor-
ticoid and adrenal androgen output by
the cells. This was corroborated by a
significant upregulation of a number of
steroidogenic enzymes. This response is
contrary to what one might have an-
ticipated considering that mitochon-
drial NADPH is an essential cofactor
to the steroidogenic cytochrome P450
enzymes CYP11A1, CYP11B1, and
CYP11B2. Elucidating the mechanisms
that drive this transient effect will re-
quire additional studies. The few studies
exploring the relationship between ROS and steroido-
genesis (mostly on testicular Leydig cell tumor cells) have
reported a downregulation of steroidogenic enzymes with
oxidative stress (14, 48–50). Human patients with inac-
tivating NNT mutations (4) and a murine Nnt deletion
model (16) have been shown to have disrupted ste-
roidogenesis; the data from our in vitro NNT KD
models suggest that NNT loss is not limiting for
adrenal steroidogenesis. Interestingly, Zhao et al. (51)
demonstrated a biphasic relationship between ROS and
steroidogenesis, indicating that the direction of the effect
is dose-dependent.
Taken together, we show that NNT silencing can
induce cytotoxicity and impede cell growth in ACC cells,
as well as sensitize them to chemically induced oxidative
stress. Moreover, we have demonstrated how the plas-
ticity of ACC cells can lead to the development of a
compensatory molecular response with time and de-
scribed how changes in polyamine metabolism and ER
protein processing are involved in this process (Fig. 7). A
limitation of our work is that it is based on a single cell
line; however, NCI-H295R remains the only established,
well-characterized steroidogenic human ACC cell line.
These results merit further exploration with in vivo
studies to corroborate the effectiveness of mitochondrial
antioxidant pathway targeting and explore its durability,
alone or in combination with other pro-oxidant agents.
The unique features of adrenocortical cells, with their
Figure 7. Response of NCI-H295R cells to NNT silencing in the acute (transient KD) and
chronic (stable KD) setting, with proposed redox adaptation mechanisms. Acute NNT KD
induces oxidative stress as predicted by the role of NNT as a major NADPH generator;
enhanced steroidogenesis and polyamine catabolism further accentuate ROS accumulation,
triggering apoptosis and a sharp decline in cell proliferation. With time (stable KD), cells
manage to adapt removing damaged proteins and enhancing spermine synthesis as an
alternative, NADPH-independent ROS scavenger. This restores redox homeostasis and
abrogates the original proapoptotic effect, but cellular proliferation remains suppressed.
Horizontal arrows represent paucity of change.
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high-volume ROS generation due to steroidogenesis,
make ACC a most amenable target to this approach.
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